Biden administration awards $500M for new COVID treatments
Source: msn.com
Story by Joseph Choi • 11h
................Intranasal vaccines are rare but not unheard of. In the U.S., the spray flu vaccine called FluMist is approved for people
aged two to 49.
Joanna Kaufman, executive vice president for oncology and immunology at Codagenix, recently spoke on the available data on her company’s intranasal vaccine candidate, CoviLiv, during a discussion with the Infectious Diseases Society of America.
Unlike the more common mRNA COVID-19 vaccines, the intranasal candidate from Codagenix is more traditional in that is uses a modified, weakened version of the virus to induce an immune response
“CoviLiv can induce a robust, systemic immune response after intranasal delivery of this live attenuated bio-vaccine,” Kaufman said, adding that her company’s vaccine induced a response that not only targeted spike proteins — as mRNA vaccines do — but also other viral proteins that mutate less...................................
Read more: https://www.msn.com/en-us/health/other/biden-administration-awards-500m-for-new-covid-treatments/ar-AA1ib0hj?ocid=socialshare&cvid=a89592dc39a04d818a7b5aacceaab310&ei=11
Link to tweet
?s=20